Comparison of the Effects of Citalopram and Escitalopram on 5-Ht-Mediated Neuroendocrine Responses

被引:0
作者
Haitham S Nadeem
Mary-Jane Attenburrow
Philip J Cowen
机构
[1] Warneford Hospital,University Department of Psychiatry
来源
Neuropsychopharmacology | 2004年 / 29卷
关键词
citalopram; escitalopram; saliva; cortisol; serotonin;
D O I
暂无
中图分类号
学科分类号
摘要
Acute oral administration of selective serotonin re-uptake inhibitors (SSRIs) increases plasma cortisol by facilitating brain serotonin activity. Recently, salivary cortisol sampling has grown in popularity as a noninvasive means of assessing HPA axis activity. The aim of the present study was to find out whether acute oral administration of the SSRI, citalopram, increases salivary cortisol in healthy volunteers and whether the increase produced by an equivalent dose of its active isomer, escitalopram, is greater. A total of 15 healthy subjects were tested on three occasions receiving either oral citalopram (20 mg), escitalopram (10 mg), or placebo in a double-blind, randomized, crossover design. Salivary cortisol and plasma cortisol and prolactin were measured for 240 min after each treatment. Relative to placebo, both citalopram and escitalopram increased salivary and plasma cortisol levels with no evidence of consistent differences between them. Plasma prolactin concentration was not altered by either active treatment. Plasma and salivary cortisol responses after citalopram but not escitalopram correlated significantly. The present study does not support an enhanced effect of escitalopram on 5-HT-mediated neuroendocrine responses.
引用
收藏
页码:1699 / 1703
页数:4
相关论文
共 78 条
[1]  
Attenburrow MJ(2001)Low-dose citalopram as a 5-HT neuroendocrine probe Psychopharmacology 155 323-326
[2]  
Mitter PR(2002)Acute citalopram administration produces correlated increases in plasma and salivary cortisol Psychopharmacology 163 118-120
[3]  
Whale R(2003)Acute changes in Cerebrospinal Fluid 5-HIAA following Oral Paroxetine Challenge in Healthy Humans Neuropsychopharmacology 28 339-347
[4]  
Terao T(2001)Measurement of citalopram in plasma by HPLC with UV detection J Psychopharmacol 15 A64-348
[5]  
Cowen PJ(1997)Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission J Psychopharmacol 11 345-139
[6]  
Bhagwagar Z(2003)Central serotonergic effects of Neuropsychopharmacology 28 133-44
[7]  
Hafizi S(2002)-chlorophenylpiperazine (mCPP) among normal control adolescents CNS Spectrums 7 40-1532
[8]  
Cowen PJ(2000)Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials Clin Ther 22 1525-71
[9]  
Carpenter Linda L(2002)Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study Int J Neuropsychopharmacol 5 67-102
[10]  
Anderson George M(2003)Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests Psychopharmacology 167 97-67